Article
Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study.
Antimicrobial agents and chemotherapy - 1 Oct 2013
Berger Kristi L, Lagacé Lisette, Triki Ibtissem, Cartier Mireille, Marquis Martin, Lawetz Carol, Bethell Richard, Scherer Joseph, Kukolj George
Abstract excerpt
Faldaprevir (BI 201335) is a selective NS3/4A protease inhibitor under development for the treatment of chronic hepatitis C virus (HCV) infection. NS3/4A genotyping and NS3 protease phenotyping analyses were performed to monitor the emergence of resistance in patients with HCV genotype 1 infection receiving faldaprevir alone or combined with pegylated interferon alfa 2a and ribavirin (PegIFN-RBV) during a phase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.